In this infographic we take a look at the estimated burden of healthcare-associated infections in acute care hospitals across Europe.
Browsing: Healthcare-associated Infections
In this interview with Trisha Peel from Monash University, she explains the issues surrounding device-related infections in addition to discussing some promising new approaches to diagnosis and treatment.
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Whole-genome sequencing has been used to demonstrate that carbapenem resistance can be transferred among unrelated bacteria species in a healthcare setting.
A study presented at ECCMID has suggested patient outcomes for Gram-negative bacteremia are similar in the case of 7 days and 14 days of antibiotic treatment, suggesting a shorter course length could be beneficial.
We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
In the era of meta-omics, infection control and prevention must consider healthcare-associated infections in the global context of pathobiome.
Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.